Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (NYSE:RCUS) will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 11:20 a.m. Eastern Time. Investors can access the live webcast via the Investors & Media section of their website. Arcus is focused on developing innovative treatments for cancer, collaborating with global partners to expedite the development of first- or best-in-class medicines. Since its founding in 2015, Arcus has initiated clinical studies for six investigational medicines targeting critical pathways in cancer treatment.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to nine new employees. A total of 13,700 options were granted at an exercise price of $24.69, the closing price on November 8, 2022, alongside 6,850 restricted stock units. These awards were made under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus focuses on developing innovative cancer therapies through clinical studies on various investigational medicines targeting key biological pathways.
Arcus Biosciences reported its Q3 2022 financial results, revealing revenues of $33.6 million, up from $9.5 million in Q3 2021, driven by collaboration with Gilead. The company holds $1.2 billion in cash, sufficient to fund operations into 2026. Arcus is advancing its clinical pipeline, focusing on anti-TIGIT therapies with three Phase 3 trials for domvanalimab in lung cancer. A strategic amendment to the ARC-10 trial design now compares domvanalimab and zimberelimab to pembrolizumab, excluding a chemotherapy arm. The trial aims to define a new standard-of-care in NSCLC.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of options and restricted stock units to 14 new employees, totaling 35,200 shares at an exercise price of $26.15, the closing price on October 10, 2022. Additionally, 17,600 shares were awarded as restricted stock units. This award is part of the company’s 2020 Inducement Plan, which complies with NYSE regulations. Arcus focuses on developing innovative cancer therapies and has advanced six investigational medicines to clinical studies.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to ten new employees, totaling 33,950 and 16,975 shares, respectively. The options were priced at $25.70, aligning with the closing price on September 8, 2022. This equity grant falls under the 2020 Inducement Plan, approved by the Board of Directors. Arcus is focused on developing innovative cancer therapies, with clinical studies underway for six investigational medicines targeting various biological pathways.
Arcus Biosciences (NYSE:RCUS) announced its participation in key investor conferences. The Citi 17th Annual BioPharma Conference will take place on September 7, 2022, in Boston, MA, featuring 1-on-1 meetings. Following this, the Morgan Stanley 20th Annual Global Healthcare Conference is scheduled for September 12, 2022, in New York, NY, with a fireside chat at 12:30 p.m. ET. A live webcast will be available on the Arcus website, with replays accessible afterward.
Arcus Biosciences, Inc. (NYSE:RCUS) announces the granting of stock options and restricted stock units to nine new employees. A total of 22,100 options were provided at an exercise price of $27.35, reflecting the closing price on August 8, 2022. Additionally, 11,050 restricted stock units were awarded. These grants are in accordance with the Company’s 2020 Inducement Plan, approved in January 2020, under NYSE Rule 303A.08. Arcus is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.
Arcus Biosciences (NYSE:RCUS) appointed Dr. Dimitry S.A. Nuyten as Chief Medical Officer effective August 1, 2022. Dr. Nuyten will lead the clinical development organization, comprising nearly 200 employees and six clinical-stage programs, including four ongoing Phase 3 trials for domvanalimab in combination therapies targeting various cancers. His extensive background includes leadership roles at Nektar Therapeutics and Pfizer. Arcus aims to expedite the development of innovative cancer treatments through collaborations, notably with Gilead, which invested $200 million into the company in 2020.
Arcus Biosciences (NYSE: RCUS) reported its second-quarter financial results, revealing collaboration and license revenues of $26.8 million, up from $9.5 million year-over-year. The company's cash position stands strong at $1.3 billion, sufficient to fund operations into 2026. Notable updates include ongoing Phase 3 trials for domvanalimab-based therapies in NSCLC and gastrointestinal cancers. The interim analysis of the ARC-8 trial for quemliclustat indicates no significant safety issues, but final data on progression-free and overall survival are awaited in 2023.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, will engage in a virtual fireside chat at the 13th Annual Wedbush PacGrow Healthcare Conference. The event is scheduled for August 10, 2022, at 12:00 p.m. ET. Interested parties can access a live webcast via the Arcus Biosciences website, with a replay available post-event. Founded in 2015, Arcus is advancing six investigational medicines aimed at targeting cancer pathways.